Big Gain For Cyclerion Therapeutics, Inc.
Fri, Nov 15, 2024 at 07:22 PM
Cyclerion Therapeutics, Inc. (CYCN:NASDAQ) soared at $2.58, representing a gain of 45.8%. On Fri, Nov 15, 2024, CYCN:NASDAQ hit a New 2-Week Intraday High of $2.99. The stock got featured on our News Catalysts scanner on Fri, Nov 08, 2024 at 08:22 PM in the 'EARNINGS' category. From Fri, Nov 01, 2024, the stock recorded 40.00% Up Days and 9.09% Green Days
About Cyclerion Therapeutics, Inc. (CYCN:NASDAQ)
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop and commercialize breakthrough treatments for serious and orphan diseases.Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators.
Top 10 Gainers:
- The Arena Group Holdings Inc. (AREN:NYSEMKT), 207.02%
- Bloom Energy Corporation (BE:NYSE), 59.19%
- CERo Therapeutics Holdings Inc Com (CERO:NASDAQ), 52.4%
- Cyclerion Therapeutics, Inc. (CYCN:NASDAQ), 45.76%
- SIMPPLE LTD. (SPPL:NASDAQ), 43.47%
- Pulmatrix, Inc. (PULM:NASDAQ), 39.57%
- Trilogy Metals Inc. (TMQ:NYSEMKT), 36.66%
- Zentek Ltd. (ZTEK:NASDAQ), 30.64%
- Solidion Technology Inc. (STI:NASDAQ), 28.63%
- Fitell Corporation (FTEL:NASDAQ), 28.55%